Loyal raised $100M Series C venture round, led by age1.
Loyal, a pioneering clinical-stage veterinary medicine company based in San Francisco, California, has successfully closed a Series C funding round, securing an impressive $100 million. This significant investment is poised to accelerate Loyal's mission: extending the healthy lifespan of senior dogs through innovative veterinary medicine.
| Investor | Firm Type | Partner |
|---|
age1LEAD | Venture Capital | — |
| Venture Capital | — |
This company has completed 4 funding rounds. Current round is highlighted.
Total Raised
$183M
Top Valuation
-
Loyal is a clinical-stage veterinary medicine company dedicated to extending the healthy lifespan of senior dogs.
Loyal successfully raised $100 million in its Series C funding round.
The funding will accelerate Loyal's clinical trials, research initiatives, and operational expansion to bring innovative treatments for senior dogs to market.
Loyal is based in San Francisco, California, United States, North America.
['### LOYAL SECURES $100M IN SERIES C FUNDING', "Loyal, a leader in veterinary medicine, has announced the completion of its Series C funding round, raising $100 million. This substantial capital infusion highlights strong investor confidence in Loyal's groundbreaking work in canine longevity and health.", '', '### ADVANCING CANINE LONGEVITY RESEARCH', "The newly acquired funds will primarily be directed towards accelerating Loyal's clinical trials and research initiatives focused on extending the healthy lifespan of senior dogs. These efforts are critical for bringing innovative treatments to market that address age-related health issues in pets.", '', '### IMPACT ON VETERINARY MEDICINE', "This funding round is a pivotal moment for the veterinary medicine sector. Loyal's dedication to developing therapies for aging dogs promises to revolutionize how veterinarians and pet owners approach senior canine care, ultimately improving the quality of life for millions of dogs worldwide.", '', '### STRATEGIC GROWTH AND EXPANSION', "With the $100 million investment, Loyal plans to expand its research and development teams, scale its operational capacity, and further strengthen its position as a frontrunner in veterinary biotechnology. The company's strategic growth is aligned with its vision of a future where dogs enjoy longer, healthier lives.", '', '### THE FUTURE OF SENIOR DOG HEALTH', "Loyal's innovative approach to veterinary medicine aims to address the root causes of age-related diseases in dogs. This Series C funding will enable the company to expedite the development and availability of treatments that could set new standards for senior dog health and wellness."]